FDA Drug recall D-0577-2022
Bortezomib, 3.5 mg/vial, Single-Dose Vial, Rx Only, Mfd
- FDA Drug
- Class III
- terminated
- Published 2022-03-02
On 2022-03-02 the FDA classified a Class III recall of Bortezomib, 3.5 mg/vial, Single-Dose Vial, Rx Only, Mfd by Dr Reddy S Laboratories, citing failed stability specifications.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0577-2022 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2022-01-19 |
| Published | 2022-03-02 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Dr Reddy S Laboratories |
| Distribution | US |
Product
Bortezomib, 3.5 mg/vial, Single-Dose Vial, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Visakhapatnam - 530 046, India, NDC 43598-865-60
Reason
Failed stability specifications
Identifiers
| code_info | Lot # H210233, Exp 3/1/2023 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0577-2022%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.